Avoro Capital Advisors LLC Takes Position in uniQure (NASDAQ:QURE)

Avoro Capital Advisors LLC purchased a new stake in shares of uniQure (NASDAQ:QURE - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 2,175,000 shares of the biotechnology company's stock, valued at approximately $38,410,000. uniQure makes up approximately 0.5% of Avoro Capital Advisors LLC's holdings, making the stock its 26th largest holding. Avoro Capital Advisors LLC owned about 4.46% of uniQure at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of QURE. Franklin Resources Inc. lifted its holdings in shares of uniQure by 33.1% during the 4th quarter. Franklin Resources Inc. now owns 1,987,688 shares of the biotechnology company's stock valued at $35,103,000 after acquiring an additional 494,726 shares in the last quarter. Invesco Ltd. raised its position in uniQure by 453.2% in the fourth quarter. Invesco Ltd. now owns 613,601 shares of the biotechnology company's stock valued at $10,836,000 after purchasing an additional 502,684 shares during the period. Geode Capital Management LLC lifted its stake in shares of uniQure by 2.3% during the fourth quarter. Geode Capital Management LLC now owns 520,553 shares of the biotechnology company's stock worth $9,198,000 after purchasing an additional 11,951 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of uniQure by 14.7% in the fourth quarter. JPMorgan Chase & Co. now owns 453,784 shares of the biotechnology company's stock worth $8,014,000 after buying an additional 58,246 shares during the period. Finally, Jump Financial LLC grew its stake in shares of uniQure by 193.5% in the fourth quarter. Jump Financial LLC now owns 211,776 shares of the biotechnology company's stock valued at $3,740,000 after buying an additional 139,624 shares in the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at uniQure

In related news, CEO Matthew C. Kapusta sold 26,727 shares of the firm's stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total transaction of $285,978.90. Following the transaction, the chief executive officer now directly owns 571,188 shares in the company, valued at $6,111,711.60. This trade represents a 4.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Christian Klemt sold 2,916 shares of the business's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total transaction of $33,009.12. Following the sale, the chief financial officer now owns 155,168 shares of the company's stock, valued at approximately $1,756,501.76. The trade was a 1.84 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 90,830 shares of company stock worth $961,401 over the last quarter. 4.74% of the stock is owned by corporate insiders.

uniQure Stock Down 0.6 %

Shares of uniQure stock traded down $0.08 during trading on Friday, reaching $14.18. The company had a trading volume of 646,241 shares, compared to its average volume of 1,767,181. The company has a market cap of $766.81 million, a price-to-earnings ratio of -2.86 and a beta of 0.42. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $19.18. The firm's fifty day moving average is $11.92 and its 200-day moving average is $11.49. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Wells Fargo & Company reduced their price target on uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a research report on Friday, February 28th. StockNews.com raised shares of uniQure to a "sell" rating in a research report on Tuesday, March 11th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $24.00 price target on shares of uniQure in a report on Tuesday, January 21st. HC Wainwright reaffirmed a "buy" rating and set a $70.00 price target on shares of uniQure in a research note on Monday. Finally, Chardan Capital assumed coverage on shares of uniQure in a research report on Tuesday, April 1st. They issued a "buy" rating and a $38.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $38.80.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.